Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.33 |
| ▸ | MPO | P05164 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | TSPO | P30536 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22904292 | 0.85 | MAOA (0.41) | MPOSLC6A4MAOAMAOBFFAR1 | |
| SCHEMBL534703 | 0.77 | CSNK2A1 (0.40) | CSNK2A1MPOSLC6A4MAOAMAOB | |
| SCHEMBL30814733 | 0.77 | CSNK2A1 (0.40) | CSNK2A1MPOSLC6A4MAOAMAOB | |
| SCHEMBL1020440 | 0.76 | PSEN1 (0.40) | MPOSLC6A4FFAR1TSPODRD3 | |
| SCHEMBL29618975 | 0.76 | PSEN1 (0.40) | MPOSLC6A4FFAR1TSPODRD3 | |
| SCHEMBL16129059 | 0.73 | ALDH1A1 (0.45) | CSNK2A1MPOSLC6A4 | |
| SCHEMBL31454495 | 0.73 | MPO (0.34) | CSNK2A1MPOSLC6A4FFAR1TSPO | |
| SCHEMBL3067018 | 0.73 | ESR1 (0.40) | MPOSLC6A4FFAR1TSPODRD3 | |
| SCHEMBL5642630 | 0.73 | KCNH2 (0.39) | CSNK2A1MPOSLC6A4 | |
| SCHEMBL31533623 | 0.73 | MAOA (0.38) | MPOSLC6A4MAOAMAOBFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2606034-B1 | PYRIMIDINE DERIVATIVE AS FAK INHIBITORS | MERCK PATENT GMBH (DE) | 2016-03-09 | — | — | EP | disclosed |
| EP-2606034-B1 | PYRIMIDINE DERIVATIVE AS FAK INHIBITORS | MERCK PATENT GMBH (DE) | 2016-03-09 | — | — | EP | disclosed |
| CN-103052627-B | As the pyrimidine derivatives of Fak inhibitor | MERCK PATENT GMBH (DE) | 2015-08-19 | — | — | CN | disclosed |
| US-8906916-B2 | Pyrimidine derivatives as FAK inhibitors | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-8906916-B2 | Pyrimidine derivatives as FAK inhibitors | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-8906916-B2 | Pyrimidine derivatives as FAK inhibitors | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| EP-2606034-A1 | PYRIMIDINE DERIVATIVES AS FAK INHIBITORS | Merck Patent GmbH (DE) | 2013-06-26 | — | — | EP | disclosed |
| US-20130158005-A1 | PYRIMIDINE DERIVATIVES AS FAK INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158005-A1 | PYRIMIDINE DERIVATIVES AS FAK INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158005-A1 | PYRIMIDINE DERIVATIVES AS FAK INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-06-20 | — | — | US | disclosed |
| CN-103052627-A | Pyrimidine derivatives as fak inhibitors | MERCK PATENT GMBH | 2013-04-17 | — | — | CN | disclosed |
| WO-2012022408-A1 | PYRIMIDINE DERIVATIVES AS FAK INHIBITORS | MERCK PATENT GMBH (DE) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012022408-A1 | PYRIMIDINE DERIVATIVES AS FAK INHIBITORS | MERCK PATENT GMBH (DE) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158005-A1 | PYRIMIDINE DERIVATIVES AS FAK INHIBITORS | CDK2, PTK2, CDKN1A | CSNK2A1 608/4885MPO 4795/4885SLC6A4 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.